Patel, N., Walter, J., Wasserman, R., Rubinstein, A., Atkinson, T. P., Shepherd, M., … Yel, L. (2023). Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease. In Clinical Immunology (Vol. 250, pp. 109598–109598). Elsevier BV. https://doi.org/10.1016/j.clim.2023.109598

Patel, Niraj, Jolan Walter, Richard Wasserman, Arye Rubinstein, T Prescott Atkinson, Meagan Shepherd, Erin Greco, et al. “Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease.” In Clinical Immunology, 250:109598–109598. Elsevier BV, 2023. https://doi.org/10.1016/j.clim.2023.109598.

Patel N, Walter J, Wasserman R, Rubinstein A, Atkinson TP, Shepherd M, et al. Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease. In: Clinical Immunology. Elsevier BV; 2023. p. 109598–109598.

Patel, Niraj, et al. “Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease.” Clinical Immunology, vol. 250, Elsevier BV, 2023, pp. 109598–109598. Crossref, doi:10.1016/j.clim.2023.109598.

Patel N, Walter J, Wasserman R, Rubinstein A, Atkinson TP, Shepherd M, Greco E, Russo-Schwarzbaum S, Duff K, McCoy B, Chu L-H, Li Z, Yel L. Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease. Clinical Immunology. Elsevier BV; 2023. p. 109598–109598.